The filing is a routine advance notice of a director's intent to sell shares acquired via option exercises. The sale amount is small relative to market cap and does not suggest any change in the company's outlook. Monitor for the actual sale on Form 4 and for any pattern of increased insider selling.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $973.36entry
- T+1 · 13d ago −4.39%α −6.04% · $930.67
- T+5 · 7d ago −5.89%α −5.30% · $916.06
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director George L. Sing filed a Form 144 notice of intent to sell 21,129 shares of Regeneron common stock, with an approximate market value of $20.4 million based on the filing. The shares to be sold were acquired through option exercises, some recent and some previously exercised. This is a routine insider sale filing by a director and does not indicate a change in company fundamentals.
Key Facts
- George L. Sing, a director of Regeneron, filed a Form 144 on November 2, 2026.
- The filing covers the proposed sale of 21,129 shares of common stock.
- The approximate market value of the proposed sale is $20,376,359.76.
- The shares were acquired through exercise of options under a registered plan and previously exercised options.
- The sale is planned for execution on or after November 2, 2026.
- The shares are to be sold through Morgan Stanley Smith Barney LLC.
Financial Impact
Proposed sale of 21,129 shares valued at approximately $20.4 million, representing about 0.02% of Regeneron's $84.3B market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not be executed.
- The filing does not disclose the insider's remaining holdings, so the proportion sold relative to total holdings is unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010543 |
| Document: 0001950047-26-010543-index.html | 0001950047-26-010543 |
| Document: 0001950047-26-010543.txt | 0001950047-26-010543 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers